CADL Candel Therapeutics Inc
Price (delayed)
$7.94
Market cap
$257.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.73
Enterprise value
$257.05M
Highlights
Candel Therapeutics's debt has decreased by 30% YoY and by 14% QoQ
Candel Therapeutics's equity has shrunk by 166% YoY and by 53% QoQ
CADL's quick ratio has dropped by 74% year-on-year and by 29% since the previous quarter
Key stats
What are the main financial stats of CADL
Market
Valuations
Earnings
Shares outstanding
32.48M
Market cap
$257.86M
Enterprise value
$257.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$35.55M
Net income
-$52.2M
EBIT
-$49.83M
EBITDA
-$48.57M
Free cash flow
-$28.67M
Per share
Balance sheet
Liquidity
EPS
-$1.73
EPS diluted
-$1.73
Free cash flow per share
-$0.9
Book value per share
-$0.48
Revenue per share
$0
TBVPS
$0.67
Total assets
$21.52M
Total liabilities
$36.77M
Debt
$16.02M
Equity
-$15.26M
Working capital
$2.82M
Debt to equity
-1.05
Current ratio
1.18
Quick ratio
1.1
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-173.4%
Return on equity
N/A
Return on invested capital
-478.4%
Return on capital employed
-797.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CADL stock price
How has the Candel Therapeutics stock price performed over time
Intraday
-1.85%
1 week
1.15%
1 month
-9.98%
1 year
405.73%
YTD
-8.53%
QTD
-8.53%
Financial performance
How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.55M
Net income
-$52.2M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 63% year-on-year and by 4.4% since the previous quarter
Growth
What is Candel Therapeutics's growth rate over time
Valuation
What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has shrunk by 59% YoY and by 2.4% QoQ
Candel Therapeutics's equity has shrunk by 166% YoY and by 53% QoQ
Efficiency
How efficient is Candel Therapeutics business performance
The company's return on invested capital fell by 40% QoQ
CADL's ROA is down by 29% from the previous quarter
Dividends
What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CADL.
Financial health
How did Candel Therapeutics financials performed over time
The total assets is 41% smaller than the total liabilities
CADL's quick ratio has dropped by 74% year-on-year and by 29% since the previous quarter
The current ratio has plunged by 73% YoY and by 27% from the previous quarter
Candel Therapeutics's equity has shrunk by 166% YoY and by 53% QoQ
CADL's debt to equity is up by 44% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.